|
1
|
Pace A and Fabi A: Chemotherapy in
neoplastic meningitis. Crit Rev Oncol Hematol. 60:194–200. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amer MH, Al-Sarraf M, Baker LH and
Vaitkevicius VK: Malignant melanoma and central nervous system
metastases: Incidence, diagnosis, treatment and survival. Cancer.
42:660–668. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosen ST, Aisner J, Makuch RW, Matthews
MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS and
Bunn PA Jr: Carcinomatous leptomeningitis in small cell lung
cancer: A clinicopathologic review of the national cancer institute
experience. Medicine (Baltimore). 61:45–53. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chamberlain MC: Neoplastic meningitis. J
Clin Oncol. 23:3605–3613. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gauthier H, Guilhaume MN, Bidard FC,
Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L
and Diéras V: Survival of breast cancer patients with meningeal
carcinomatosis. Ann Oncol. 21:2183–2187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yust-Katz S, Garciarena P, Liu D, Yuan Y,
Ibrahim N, Yerushalmi R, Penas-Prado M and Groves MD: Breast cancer
and leptomeningeal disease (LMD): Hormone receptor status
influences time to development of LMD and survival from LMD
diagnosis. J Neurooncol. 114:229–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niwińska A, Rudnicka H and Murawska M:
Breast cancer leptomeningeal metastasis: Propensity of breast
cancer subtypes for leptomeninges and the analysis of factors
influencing survival. Med Oncol. 30:4082013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yap HY, Yap BS, Tashima CK, DiStefano A
and Blumenschein GR: Meningeal carcinomatosis in breast cancer.
Cancer. 42:283–286. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lara-Medina F, Crismatt A,
Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernández L,
González-Pinedo M, Gamboa-Vignolle C, Ruiz-González JD and Arrieta
O: Clinical features and prognostic factors in patients with
carcinomatous meningitis secondary to breast cancer. Breast J.
18:233–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meattini I, Livi L, Saieva C, Franceschini
D, Marrazzo L, Greto D, Scotti V, Scoccianti S, Paiar F, Bordi L,
et al: Prognostic factors and clinical features in patients with
leptominengeal metastases from breast cancer: A single center
experience. J Chemother. 24:279–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glantz MJ, Van Horn A, Fisher R and
Chamberlain MC: Route of intracerebrospinal fluid chemotherapy
administration and efficacy of therapy in neoplastic meningitis.
Cancer. 116:1947–1952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Torrejón D, Oliveira M, Cortes J,
Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A and Di
Cosimo S: Implication of breast cancer phenotype for patients with
leptomeningeal carcinomatosis. Breast. 22:19–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Azevedo CR, Cruz MR, Chinen LT, Peres
SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF and Gimenes
DL: Meningeal carcinomatosis in breast cancer: Prognostic factors
and outcome. J Neurooncol. 104:565–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le Rhun E, Zairi F, Baranzelli MC,
Faivre-Pierret M, Devos P and Bonneterre J: Primary breast cancer
phenotype associated with propensity for leptomeningeal metastases.
EJC Supplements. 8:1992010. View Article : Google Scholar
|
|
16
|
Niwińska A, Murawska M and Pogoda K:
Breast cancer subtypes and response to systemic treatment after
whole-brain radiotherapy in patients with brain metastases. Cancer.
116:4238–4247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jayson GC and Howell A: Carcinomatous
meningitis in solid tumours. Ann Oncol. 7:773–786. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lamovec J and Zidar A: Association of
leptomeningeal carcinomatosis in carcinoma of the breast with
infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab
Med. 115:507–510. 1991.PubMed/NCBI
|
|
19
|
Chamberlain MC and Johnston SK: Neoplastic
meningitis: Survival as a function of cerebrospinal fluid cytology.
Cancer. 115:1941–1946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karnofsky DA and Burchenal JH: The
clinical evaluation of chemotherapeutic agents in cancer.
Evaluation of Chemotherapeutic Agents. MacLeod CM: Columbia
University Press; New York, NY: pp. pp191–205. 1949
|
|
21
|
Boogerd W, Hart AA, van der Sande JJ and
Engelsman E: Meningeal carcinomatosis in breast cancer. Prognostic
factors and influence of treatment. Cancer. 67:1685–1695. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chamberlain MC and Kormanik PA: Prognostic
significance of coexistent bulky metastatic central nervous system
disease in patients with leptomeningeal metastases. Arch Neurol.
54:1364–1368. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Glantz MJ, Hall WA, Cole BF, Chozick BS,
Shannon CM, Wahlberg L, Akerley W, Marin L and Choy H: Diagnosis,
management, and survival of patients with leptomeningeal cancer
based on cerebrospinal fluid-flow status. Cancer. 75:2919–2931.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mego M, Sycova-Mila Z, Obertova J, Rajec
J, Liskova S, Palacka P, Porsok S and Mardiak J: Intrathecal
administration of trastuzumab with cytarabine and methotrexate in
breast cancer patients with leptomeningeal carcinomatosis. Breast.
20:478–480. 2011. View Article : Google Scholar : PubMed/NCBI
|
